KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Return on Sales (2016 - 2025)

Rigel Pharmaceuticals has reported Return on Sales over the past 16 years, most recently at 3.84% for Q4 2025.

  • Quarterly results put Return on Sales at 3.84% for Q4 2025, up 359.0% from a year ago — trailing twelve months through Dec 2025 was 1.25% (up 115.0% YoY), and the annual figure for FY2025 was 1.25%, up 115.0%.
  • Return on Sales for Q4 2025 was 3.84% at Rigel Pharmaceuticals, up from 0.4% in the prior quarter.
  • Over the last five years, Return on Sales for RIGL hit a ceiling of 3.84% in Q4 2025 and a floor of 1.64% in Q1 2022.
  • Median Return on Sales over the past 5 years was 0.12% (2023), compared with a mean of 0.04%.
  • Biggest five-year swings in Return on Sales: tumbled -213bps in 2022 and later soared 359bps in 2025.
  • Rigel Pharmaceuticals' Return on Sales stood at 1.11% in 2021, then skyrocketed by 102bps to 0.03% in 2022, then fell by -25bps to 0.02% in 2023, then surged by 1109bps to 0.25% in 2024, then skyrocketed by 1442bps to 3.84% in 2025.
  • The last three reported values for Return on Sales were 3.84% (Q4 2025), 0.4% (Q3 2025), and 0.59% (Q2 2025) per Business Quant data.